451 related articles for article (PubMed ID: 34920733)
1. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J; Hyötyläinen T; Orešič M; Nyström T
Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
[TBL] [Abstract][Full Text] [Related]
2. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
3. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.
Zobel EH; Wretlind A; Ripa RS; Rotbain Curovic V; von Scholten BJ; Suvitaival T; Hansen TW; Kjær A; Legido-Quigley C; Rossing P
BMJ Open Diabetes Res Care; 2021 Sep; 9(1):. PubMed ID: 34518158
[TBL] [Abstract][Full Text] [Related]
4. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
[TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.
Usui R; Yabe D; Kuwata H; Murotani K; Kurose T; Seino Y
J Diabetes Complications; 2015; 29(8):1203-10. PubMed ID: 26279320
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
[TBL] [Abstract][Full Text] [Related]
9. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR;
Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095
[TBL] [Abstract][Full Text] [Related]
11. Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.
Guarnotta V; Bianco MJ; Vigneri E; Panto' F; Lo Sasso B; Ciaccio M; Pizzolanti G; Giordano C
Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3193-3201. PubMed ID: 34518091
[TBL] [Abstract][Full Text] [Related]
12. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
13. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
14. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
[TBL] [Abstract][Full Text] [Related]
17. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
18. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Rizzo M; Rizvi AA; Patti AM; Nikolic D; Giglio RV; Castellino G; Li Volti G; Caprio M; Montalto G; Provenzano V; Genovese S; Ceriello A
Cardiovasc Diabetol; 2016 Dec; 15(1):162. PubMed ID: 27912784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]